ADULT MEDICATION GUIDELINE	
Naproxen	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer.	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding

Restrictions

Formulary: Unrestricted

Medication Class

Nonselective non-steroidal anti-inflammatory drug (NSAID)

Presentation

Immediate Release (IR) Tablets: 250 mg, 500 mg

Modified Release (SR) Tablets: 750 mg, 1 g

Storage

Store at room temperature, below 30°C. Protect from light.

Dose

Pain and Inflammation

Oral:

IR tablets: 250 mg to 500 mg twice daily

SR tablets: 750 mg to 1000 mg once daily

Maximum daily dose: 1250 mg

Period pain

Oral:

IR tablets: 500 mg initially, followed by 250 mg every 6 to 8 hours as required.

Heavy menstrual bleeding

Oral:

IR tablets: 500 mg initially, followed by 250 mg every 6 to 8 hours. Start just before or at onset of menstrual bleeding and continue for up to 5 days.

Migraine

Oral:

IR tablets: 750 mg initially, followed by 250–500 mg after at least 1 hour, if needed.

Administration

Oral

Take with or shortly after food.

SR tablets: swallow whole; do not break, chew or crush.

Monitoring

Renal: avoid use in severe impairment (CrCl <25mL/min). Ensure adequate hydration.

Hepatic: contraindicated in severe impairment

Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Consider alternative

3rd Trimester: Consider alternative

For more information, please contact KEMH Obstetric Medicines Information Service.

Breastfeeding

Considered safe to use

Comments

550 mg of naproxen sodium is equivalent to 500 mg of naproxen (e.g. *Naprogesic, Anaprox brands*)

Regular oral NSAIDs may be commenced 12 hours after IV parecoxib or rectal diclofenac.

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Breast inflammation and infection: Mastitis and breast abscess

Pain: Acute on chronic pelvic pain management

Palliative care (adults)

WNHS Pharmaceutical and Medicines Management Guidelines:

Pre-operative Medication Management

References

Australian Medicines Handbook. Naproxen. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2025 [cited 2025 Mar 19]. Available from: https://amhonline.amh.net.au/

AusDI. Naproxen (Systemic). In: AusDI [Internet]. St. Leonards: Health Communication Network Limited; 2025 [cited 2025 Mar 19]. Available from: https://ausdi.hcn.com.au/

Therapeutic Guidelines. Heavy menstrual bleeding (menorrhagia). In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2025 [cited 2025 Mar 19]. Available from: https://app-tg-org-au.kelibresources.health.wa.gov.au/

The Royal Women's Hospital. Naproxen. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2025 [cited 2025 Mar 19]. Available from: https://thewomenspbmg.org.au/

Keywords	Naproxen, NSAID, NSAIDs, anti-inflammatory, analgesia, pain, headache, migraine, heavy menstrual bleeding, mastitis, dysmenorrhea, period pain, inza, naprosyn				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	6.0				
Date First Issued:	01/12/2014	Last Reviewed:	May 2025	Review Date:	May 2030
Endorsed by:	Medicines and Therapeutics Committee			Date:	03/06/2025
NSQHS Standards Applicable:	☒ Std 1: Clinical Governance ☐ Std 2: Partnering with Consumers ☐ Std 3: Preventing and Controlling Healthcare Associated Infection ☒ Std 4: Medication Safety			☐ Std 5: Comprehensive Care ☐ Std 6: Communicating for Safety ☐ Std 7: Blood Management ☐ Std 8: Recognising and Responding to Acute Deterioration	
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2025

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.